The Chairman & CEO of NuVasive (NASDAQ: NUVA) is Buying Shares

By Carrie Williams

Today, the Chairman & CEO of NuVasive (NASDAQ: NUVA), Gregory Lucier, bought shares of NUVA for $291.4K.

Following this transaction Gregory Lucier’s holding in the company was increased by 4.63% to a total of $6.69 million.

Based on NuVasive’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $272 million and quarterly net profit of $23.96 million. In comparison, last year the company earned revenue of $271 million and had a net profit of $6.38 million. The company has a one-year high of $81.68 and a one-year low of $44.62. NUVA’s market cap is $2.46B and the company has a P/E ratio of 31.19.

20 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 12 analyst ratings, the analyst consensus is Strong Buy with an average price target of $65, reflecting a -24.0% downside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.